harles River Laboratories (CRL.N) raised its annual profit forecast on Wednesday after the contract drug developer beat quarterly profit and revenue estimates on stronger demand for its drug discovery and development services from biotechs. Clinical research organizations have shown signs of improvement as biotech and pharmaceutical companies increase spending on research and manufacturing after a prolonged post-pandemic slowdown.
Read the full article: Charles River Lifts Profit Forecast on Improving Biotech Demand //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/charles-river-lifts-profit-forecast-improving-biotech-demand-2026-08-05/